项与 IL-6 x CK1α x TNF-α x IKZF1 x IL-2 x IFNγ x CRBN x IKZF3 x DNMT1 相关的临床试验
NCT01053806
/ Unknown status临床2期IIT
A PHASE 2, SINGLE ARM STUDY TO DETERMINE THE SAFETY AND EFFICACY OF AZACITIDINE, AND LENALIDOMIDE IN HIGHER RISK MYELODYSPLASTIC SYNDROME
To evaluate the overall response rate of the combination of 5-azacitidine + Lenalidomide in high risk MDS patients (INT-2 and High risk defined by IPSS), and patients with low and int-1 who are considered to be at high risk due to unfavorable additional factors. To evaluate the safety of the combination of 5-azacitidine + Lenalidomide in high risk MDS patients. To evaluate the hematological improvement rate. To evaluate the cytogenetic response rate. To evaluate the Progression free survival (PFS). To assess Quality of life.